Aims ACE‐inhibitors, β‐blockers, implantable cardioverter–defibrillator (ICD) and cardiac
resynchronization therapy (CRT) improved prognosis of heart failure. We sought to analyse …

Aim Contemporary survival trends in dilated cardiomyopathy (DCM) are largely unknown.
The aim of this study is to investigate clinical descriptors, survival trends and the prognostic …

Background—Contemporary therapeutic options have led to substantial improvement in
survival of patients with heart failure. However, limited evidence is available specifically on …

Objective—To analyse the changes in mortality in dilated cardiomyopathy over the past 15
years and to identify the factors that might have influenced survival. Design—Follow up …

Simple Summary Given the high morbidity and mortality linked with heart failure and the
need for disease-specific treatment, there is international agreement that there is a …

To assess the proportion and long-term outcomes of patients with idiopathic dilated
cardiomyopathy and potential indications for implantable cardioverter-defibrillator before …

Background Because of their favorable prognostic effects, angiotensin converting enzyme
inhibitors (ACEI), angiotensin II receptor blockers (ARB) and β blockers have become …

Aims Clinical parameters are weak predictors of outcome in patients with idiopathic dilated
cardiomyopathy (IDC). We assessed the prognostic value of cardiac magnetic resonance …

A study of factors predicting mortality was performed in 201 patients with dilated
cardiomyopathy (163 men, 38 women, mean age: 48±11 years) by multivariate analysis …

Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by left ventricular or
biventricular dilation and impaired contraction that is not explained by abnormal loading …